Dr. Aurel-Damian Roscher, LL.M.

慕尼黑德国

奖励

JUVE Awards 2023

Law firm of the year for IP Law

Aurel-Damian is a member of the Practice Area Patents Technology & Life Sciences. He advises national and international companies and represents them in disputes in and out of court. He primarily advises companies from the life sciences sector.

CV

Since 2023 Senior Associate, Taylor Wessing

2020 - 2023 Associate, Taylor Wessing

2016 – 2018 Trainee lawyer, research assistant and qualified lawyer at several major international law firms

职业发展

Since 2023 Senior Associate, Taylor Wessing

2020 - 2023 Associate, Taylor Wessing

2016 – 2018 Trainee lawyer, research assistant and qualified lawyer at several major international law firms

教育

2023 Doctoral degree, University of Regensburg

2020 Admitted to the Bar, district of the OLG Munich

2016 Second state examination, Berlin

语言

奖励

JUVE Awards 2023

Featured

最新新闻和观点

View Aurel-Damian's insights

点击此处了解更多

公司/并购与资本市场

Taylor Wessing advises Balderton Capital on Prior Labs’ financing round

2025年2月7日

作者

专利与创新

Claiming the clock: Mastering patent limitation periods and their impact on contract design| Life Sciences Quarterly #2

2024年10月15日

In-depth analysis

作者 Dr. Anja Lunze, LL.M. 以及 Dr. Aurel-Damian Roscher, LL.M.

点击此处了解更多

Artificial intelligence

Artificial Intelligence and Patent Law

2024年9月20日

Briefing

作者 Dr. Aurel-Damian Roscher, LL.M.

点击此处了解更多

Dr. Aurel-Damian Roscher, LL.M.

JUVE Awards 2023

专长

执业领域和服务团队

行业

CV

职业发展

教育

语言

奖励

JUVE Awards 2023

最新新闻和观点

Taylor Wessing advises Balderton Capital on Prior Labs’ financing round

与我会面：

Dr. Aurel-Damian Roscher, LL.M.

JUVE Awards 2023

专长

执业领域和服务团队

行业

CV

职业发展

教育

语言

奖励

JUVE Awards 2023

最新新闻和观点

Taylor Wessing advises Balderton Capital on Prior Labs’ financing round

Related news & insights

Episode 5: How is substantive law developing in the Unified Patent Court (UPC)?

News Flash: Employer’s Copyright Banned (ONB-decision)

Unpacking the Dutch Leadiant cases: a legal battle with significant implications for the pharmaceutical industry

New product liability risks for AI products

Purpose limitation and data minimisation: key considerations for AI training in the life sciences sector

UK approach to regulating AI in Life Sciences

Selecting your AIA notified body

Re-use of patient data in scientific research to train AI systems - important GDPR considerations

The regulation of clinical trials in which AI is deployed

Data privacy in AI due diligence

相关人员

与我会面：